Ocular Inflammation - Pipeline Review - H2 2013





Published: October 2013 | Pages: 85 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Ocular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ocular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Inflammation. Ocular Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  A snapshot of the global therapeutic scenario for Ocular Inflammation. 
  •  A review of the Ocular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Ocular Inflammation pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 

 Reasons to buy 

 

  •  Identify and understand important and diverse types of therapeutics under development for Ocular Inflammation. 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Ocular Inflammation pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

 Additional Information 

 Country 

 Global 

 Sector 

 Ophthalmology 

 Introduction 

 Global Markets Direct Report Coverage 

 Ocular Inflammation Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Ocular Inflammation 

 Ocular Inflammation Therapeutics under Development by Companies 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Early Clinical Stage Products 

 Comparative Analysis 

 Discovery and Pre-Clinical Stage Products 

 Comparative Analysis 

 Ocular Inflammation Therapeutics - Products under Development by Companies 

 Companies Involved in Ocular Inflammation Therapeutics Development 

 Bausch & Lomb Incorporated 

 AlphaRx, Inc. 

 Sun Pharmaceutical Industries Limited 

 Bayer AG 

 InSite Vision Incorporated 

 SCYNEXIS, Inc. 

 Xigen SA 

 SIFI S.p.A 

 Morria Biopharmaceuticals Plc 

 Cancer Therapeutics CRC Pty Ltd 

 Kala Pharmaceuticals 

 Icon Bioscience, Inc. 

 Laboratorios Sophia S.A. de C.V. 

 Eleven Biotherapeutics 

 Ocular Inflammation - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Combination Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 ISV-303 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 ketorolac tromethamine - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 dexamethasone acetate - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 XG-102 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 dexamethasone acetate - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 mapracorat - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 SF-110 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 SF-111 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 SF-101 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 SF-105 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 (tobramycin + prednisolone acetate) - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 RX-10045 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 OPX-1 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 SCY-641 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 NOP-5 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 PRO-155 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 EBI-005 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Sun-0597 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 dexamethasone acetate SR - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 triamcinolone acetonide - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Drug Targeting LIM-Kinase 1 And 2 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Ocular Inflammation Therapeutics - Drug Profile Updates 

 Ocular Inflammation Therapeutics - Discontinued Products 

 Ocular Inflammation Therapeutics - Dormant Products 

 Ocular Inflammation - Product Development Milestones 

 Featured News & Press Releases 

 Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 

 Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 

 Sep 24, 2013: Eleven Biotherapeutics to Present at the Targeting Ocular Disorders Conference 

 Jun 03, 2013: Ocular Therapeutix Completes Enrollment In Phase II Study For Sustained Release Dexamethasone 

 May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations 

 May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 

 May 08, 2013: Eleven Biotherapeutics Presents Clinical Data On EBI-005 At ARVO 2013 Annual Meeting 

 Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 

 Apr 24, 2013: Eleven Biotherapeutics To Present Data On Lead Drug Candidate EBI-005 At ARVO 2013 Annual Meeting 

 Apr 17, 2013: Bausch + Lomb Launches Prolensa At ASCRS Annual Meeting 2013 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Ocular Inflammation, H2 2013 

 Products under Development for Ocular Inflammation - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Early Clinical Stage Development, H2 2013 

 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Bausch & Lomb Incorporated, H2 2013 

 AlphaRx, Inc., H2 2013 

 Sun Pharmaceutical Industries Limited, H2 2013 

 Bayer AG, H2 2013 

 InSite Vision Incorporated, H2 2013 

 SCYNEXIS, Inc., H2 2013 

 Xigen SA, H2 2013 

 SIFI S.p.A, H2 2013 

 Morria Biopharmaceuticals Plc, H2 2013 

 Cancer Therapeutics CRC Pty Ltd, H2 2013 

 Kala Pharmaceuticals, H2 2013 

 Icon Bioscience, Inc., H2 2013 

 Laboratorios Sophia S.A. de C.V., H2 2013 

 Eleven Biotherapeutics, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Combination Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Ocular Inflammation Therapeutics - Drug Profile Updates 

 Ocular Inflammation Therapeutics - Discontinued Products 

 Ocular Inflammation Therapeutics - Dormant Products 

 List of Figures 

 Number of Products under Development for Ocular Inflammation, H2 2013 

 Products under Development for Ocular Inflammation - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Early Clinical Stage Products, H2 2013 

 Discovery and Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Combination Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013